Veracyte VCYT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70.9%+0.8pp | 70.1%+1.6pp | 68.5%+0.3pp | 68.3%+0.2pp | 68%+1.1pp | |
| Operating margin | 14.3%+3.1pp | 11.2%+6.2pp | 5%+2.1pp | 2.9%-2.2pp | 5.1%+1.5pp | |
| Net margin | 16.2%+3.4pp | 12.8%+6.7pp | 6.1%+0.6pp | 5.5%-1.6pp | 7.1%+1.7pp | |
| EBITDA margin | 18.3%+3.0pp | 15.3%+5.8pp | 9.5%+1.8pp | 7.7%-2.4pp | 10.1%+1.2pp | |
| Free cash flow margin | 28.7%+4.2pp | 24.5%+4.7pp | 19.8%+2.3pp | 17.5%+0.6pp | 16.9%+2.6pp | |
| Returns | ||||||
| Return on equity | 6.9%+1.6pp | 5.3%+2.8pp | 2.5%+0.3pp | 2.2%-0.6pp | 2.9%+0.7pp | |
| Return on assets | 6.4%+1.5pp | 4.9%+2.6pp | 2.3%+0.3pp | 2%-0.6pp | 2.6%+0.6pp | |
| Return on invested capital | 7.1%+1.3pp | 5.9%+3.3pp | 2.6%+1.2pp | 1.4%-1.0pp | 2.4%+0.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 9.3×+1.2× | 8.1×+1.9× | 6.2×+0.8× | 5.4×+0.3× | 5.1×+0.4× | |
| Quick ratio | 9.3×+1.5× | 7.8×+1.9× | 5.9×+0.8× | 5.1×+0.3× | 4.8×+0.3× | |
| Cash ratio | 4.7×-1.4× | 6.1×+1.7× | 4.4×+1.5× | 2.9×+0.4× | 2.5×-0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -2.3×+1.8× | -4.1×+1.8× | -5.9×-1.2× | -4.6×-1.7× | -2.9×+1.9× | |
| Per Share | ||||||
| Book value per share | $16.53+1.7% | $16.25+3.0% | $15.78+1.3% | $15.58+4.4% | $14.93-0.8% | |
| Valuation | ||||||
| Market capitalization | $2.56B-23.1% | $3.33B+23.2% | $2.7B+28.3% | $2.11B-8.9% | $2.31B-24.7% | |
| Enterprise value | $2.33B-22.3% | $3B+23.9% | $2.42B+25.3% | $1.93B-11.0% | $2.17B-24.5% | |
| Price / earnings | 29.1×-21.1× | 50.2×-38.9× | 89.1×+9.1× | 79.9×+10.0× | 69.9×-57.2× | |
| Price / sales | 4.7×-1.7× | 6.4×+1.0× | 5.5×+1.1× | 4.4×-0.6× | 5×-1.9× | |
| Price / book | 1.9×-0.6× | 2.5×+0.4× | 2.1×+0.4× | 1.7×-0.2× | 1.9×-0.7× | |
| EV / EBITDA | 23.6×-14.4× | 37.9×-13.5× | 51.4×-1.1× | 52.6×+6.2× | 46.3×-26.4× | |
| EV / sales | 4.3×-1.5× | 5.8×+0.9× | 4.9×+0.9× | 4×-0.7× | 4.7×-1.8× | |
| Free cash flow yield | 6.1%+2.3pp | 3.8%+0.2pp | 3.6%-0.4pp | 4%+0.6pp | 3.4%+1.3pp | |
| Earnings yield | 3.4%+1.4pp | 2%+0.9pp | 1.1%-0.1pp | 1.3%-0.2pp | 1.4%+0.6pp | |
| PEG ratio | 0.2×-0.1× | 0.3×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Veracyte's profit margins?
- Veracyte (VCYT) runs a 70.9% gross margin and a 14.3% operating margin, with a 16.2% net margin.
- Where do Veracyte's ratios come from?
- Every ratio is computed from Veracyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.